RT Journal Article
T1 Switch to subcutaneous infliximab during the SARS-CoV-2 pandemic: preliminary results.
A1 Argüelles-Arias, Federico
A1 Fernández Álvarez, Paula
A1 Castro Laria, Luisa
A1 Maldonado Pérez, Belén
A1 Belvis Jiménez, María
A1 Merino-Bohórquez, Vicente
A1 Caunedo Álvarez, Ángel
A1 Calleja Hernández, Miguel Ángel
AB A new subcutaneous formulation of the infliximab biosimilar CT-P13 has recently been developed for the treatment of inflammatory bowel disease (IBD), providing response rates similar to intravenous treatment. The use of this new formulation was requested, in an effort to limit patient attendance at intravenous infusion centers and to maintain biological treatment during the COVID-19 pandemic. The objective of this observational, retrospective and descriptive study was to assess CT-P13 efficacy and safety after switching from intravenous to a subcutaneous formulation in patients with IBD receiving maintenance therapy. This article shows preliminary results after six months of follow-up.
SN 1130-0108
YR 2022
FD 2022
LK http://hdl.handle.net/10668/21716
UL http://hdl.handle.net/10668/21716
LA en
DS RISalud
RD Apr 8, 2025